ReSTOR IOL good in post LASIK cataract patients

Article

The use of the ReSTOR intraocular lens (IOL) (Alcon) for patients requiring cataract surgery after prior laser photoablation can result in excellent outcomes if optical results fall near emmetropia, according to Samuel Masket of the USA.

The use of the ReSTOR intraocular lens (IOL) (Alcon) for patients requiring cataract surgery after prior laser photoablation can result in excellent outcomes if optical results fall near emmetropia, according to Samuel Masket of the USA.

A total of 16 eyes of 11 patients were chosen to receive the lens after discussing thoroughly the risks, benefits and alternative lens options. Presurgical biometry was performed by partial coherence interferometry and appropriate formulae applied for IOL power calculation.

Surgery was performed using topical and intracameral anaesthesia employing phacoemulsification through clear corneal temporal incisions. Five patients underwent bilateral surgery while the remaining six required surgery in just one eye.

The results showed that all five bilateral patients were fully independent of spectacles after surgery and that, in all, ten of the eleven patients were very satisfied with the visual outcomes. One patient was moderately dissatisfied despite achieving 20/25 and J2+ uncorrected visual acuities. There were no complications of surgery and no IOLs were removed or exchanged.

Masket concluded that the ReSTOR IOL offers a good option for patients needing cataract surgery after laser photoablation.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.